The invention claimed is:

1. Crystalline (3S)-Tetrahydrofuran-3-yl (4S)-4-isopropyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate mesylate salt having the space group P2(1)2(1)2(1), and unit cell dimensions substantially as follows:

a	8.75780(10)Å	α	90°
b	9.70830(10)Å,	β	90°,
c	20.6736(2)Å,	γ	90°.

2. Crystalline (3S)-Tetrahydrofuran-3-yl (4S)-4-isopropyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate mesylate salt having an XRPD pattern containing the following 2θ value measured using CuKα radiation: 21.948.

3. The salt according to claim **2** having an XRPD pattern containing the following 2θ values measured using CuKα radiation: 17.744 and 21.948.

4. The salt according to claim **2** having an XRPD pattern containing the following 2θ values measured using CuKα radiation: 17.744, 20.886, 21.948.

5. The salt according to claim **2** having an XRPD pattern containing the following 2θ values measured using CuKα radiation: 17.744, 20.886, 21.948, and 9.851.

6. The salt according to claim **2** having an XRPD pattern containing the following 2θ values measured using CuKα radiation: 17.744, 20.886, 21.948, 9.851 and 16.280.

7. The salt according to claim **2** having an XRPD pattern containing the following 2θ values measured using CuKα radiation: 9.851, 16.280, 17.097, 17.744, 19.694, 20.443, 20.886, 21.948, 22.112, 23.194, 23.653, 24.144, 27.084, 27.283 and 29.912.

8. The salt according to claim **2** having an XRPD pattern as set out in Table 4 and/or FIG. **2**.

9. A salt according to claim **1** having a purity of greater than 95%.

10. A salt according to claim **1** having a purity of greater than 99%.

11. A salt according to claim **1** having a purity of greater than 99.5%.

12. A salt according to claim **1** having an enantiomeric purity of greater than 95%.

13. A salt according to claim **1** having an enantiomeric purity of greater than 99%.

14. A salt according to claim **1** having an enantiomeric purity of greater than 99.5%.

15. A pharmaceutical composition comprising a salt according to claim **1**, and one or more suitable excipients.

16. A process of making crystalline (3S)-Tetrahydrofuran-3-yl (4S)-4-isopropyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c] pyridine-5-carboxylate mesylate salt by forming the mesylate salt from the free base of (3S)-Tetrahydrofuran-3-yl (4S)-4-isopropyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate.

17. A process according to claim **16** wherein the mesylate salt is formed by addition of methanesulphonic acid to the free base.

18. Crystalline (3S)-Tetrahydrofuran-3-yl (4S)-4-isopropyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate mesylate obtained by the process according to claim **16**.